Fate Therapeutics, Inc. (NASDAQ:FATE) enjoyed a 85.11% run-up in share price since hitting record low of $7.6. The stock managed 5.55% rise and now stands at $14.07 as of 02/08/2019. At recent session, the prices were hovering between $13.07 and $14.08. This company shares are 30.99% off its target price of $18.43 and the current market capitalization stands at $859.96M. The recent change has given its price a -5.04% deficit over SMA 50 and -21.75% deficit over its 52-week high. The stock witnessed -18.76% declines, -3.1% declines and 22.77% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found FATE’s volatility during a week at 7.72% and during a month it has been found around 6.81%.Fate Therapeutics, Inc. (FATE) Top Holders
Institutional investors currently hold around $811 million or 87% in FATE stock. Look at its top three institutional owners. Redmile Group, Llc owns $148.81 million in Fate Therapeutics, Inc., which represents roughly 17.3% of the company’s market cap and approximately 18.35% of the institutional ownership. Similar statistics are true for the second largest owner, Fmr Llc, which owns 7,637,402 shares of the stock are valued at $107.46 million. The third largest holder is Franklin Resources Inc, which currently holds $75.39 million worth of this stock and that ownership represents nearly 8.77% of its market capitalization.Fate Therapeutics, Inc. 13F Filings
At the end of September reporting period, 80 institutional holders increased their position in Fate Therapeutics, Inc. (NASDAQ:FATE) by some 15,700,404 shares, 34 decreased positions by 1,506,919 and 16 held positions by 40,407,396. That puts total institutional holdings at 57,614,719 shares, according to SEC filings. The stock grabbed 30 new institutional investments totaling 4,533,128 shares while 9 institutional investors sold out their entire positions totaling 109,114 shares.Fate Therapeutics, Inc. (NASDAQ:FATE) Insider Trades
Multiple company employees have indulged in significant insider trading. Fate Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Nashat Amir has sold 53,017 shares of Fate Therapeutics, Inc. (FATE) in trading session dated Jan. 30, 2019. These shares are worth $750,721 and were traded at $14.16 each. The SEC filing shows that Nashat Amir performed a sale of 97,500 shares. The Director disposed these shares by way of transaction on Jan. 29, 2019. The company’s shares were given away at $14.16 per share worth to an income of some $1,380,600 on account of Nashat Amir.
Director, Nashat Amir, sold 70,000 common shares of Fate Therapeutics, Inc. (FATE) in the open market. In a transaction dated Jan. 28, 2019, the shares were put up for sale at an average price of $13.78, raking in a sum of $964,600. After this sale, 6,499,079 common shares of FATE are directly owned by the insider, with total stake valued at $91,442,042.
In the transaction dated Jan. 25, 2019, the great number of shares disposed came courtesy the Director; Nashat Amir disposed a total of 90,000 shares at an average price of $14.14, amounting to approximately $1,272,600. The insider now directly owns 6,780,299 shares worth $95,398,807.Fate Therapeutics, Inc. (FATE) Analyst Guide
Several analysts have released their opinion on Fate Therapeutics, Inc. (NASDAQ:FATE), with 4 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.75 average brokerage recommendation.